These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35685754)

  • 1. Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices.
    Tan R; Cassoli L; Yan Y; Shen V; Day BM; Mitchell EP
    Front Public Health; 2022; 10():859113. PubMed ID: 35685754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.
    Skinner KE; Haiderali A; Huang M; Schwartzberg LS
    Future Oncol; 2021 Mar; 17(8):931-941. PubMed ID: 33207944
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
    Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
    Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
    Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
    Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
    Kimura T; Takami T; Piao Y; Ntalla I; Saji S
    Breast Cancer Res Treat; 2024 Jul; 206(1):91-103. PubMed ID: 38704772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
    Cabel L; Carton M; Pistilli B; Dalenc F; Vanlemnens L; Levy C; Jacot W; Debled M; Loeb A; Hennequin A; De la Motte Rouge T; Laborde L; Laurent C; Chamorey E; Parent D; Petit T; Mouret-Reynier MA; Campone M; Perrocheau G; Labreveux C; Bachelot T; Robain M; Lerebours F
    Breast; 2021 Apr; 56():18-25. PubMed ID: 33561617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
    Grinda T; Antoine A; Jacot W; Cottu PH; de la Motte Rouge T; Frenel JS; Mailliez A; Dalenc F; Goncalves A; Clatot F; Mouret Reynier MA; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Arnedos M; Chevrot M; Courtinard C; Tredan O; Brain E; Pérol D; Pistilli B; Delaloge S
    Eur J Cancer; 2023 Aug; 189():112935. PubMed ID: 37385070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment
    Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
    Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    Jin J; Gao Y; Zhang J; Wang L; Wang B; Cao J; Shao Z; Wang Z
    BMC Cancer; 2018 Apr; 18(1):446. PubMed ID: 29673325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy.
    Chen Y; Zhang J; Hu XC; Wang BY; Wang ZH; Wang LP; Cao J; Tao ZH; Du YQ; Zhao YN; Gong CC; Jin J
    Ann Palliat Med; 2020 Sep; 9(5):3018-3027. PubMed ID: 32787354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier.
    Chung WP; Yang CT; Chen HY; Su CY; Su HW; Ou HT
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):319-328. PubMed ID: 34006465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of African-American compared to White-American patients with early-stage breast cancer, stratified by phenotype.
    Lehrberg A; Davis MB; Baidoun F; Petersen L; Susick L; Jenkins B; Chen Y; Ivanics T; Rakitin I; Bensenhaver J; Proctor E; Nathanson SD; Newman LA
    Breast J; 2021 Jul; 27(7):573-580. PubMed ID: 33738890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
    Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
    Srimuninnimit V; Pornpraserthsuk P; Chaiwerawattana A; Kongdan Y; Namkanisorn T; Somwangprasert A; Jatuparisuthi C; Puttawibul P; Vongsaisuwan M; Thongthieang L; Bandidwattanawong C; Tantimongkolsuk C
    PLoS One; 2018; 13(12):e0209040. PubMed ID: 30566471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive Subsets of Metastatic Triple Negative Breast Cancer.
    Singh J; Asad S; Zhang Y; Nock W; Adams E; Damicis A; Ramaswamy B; Williams N; Parsons HA; Adalsteinsson VA; Winer EP; Lin NU; Partridge AH; Overmoyer B; Stover DG
    Clin Breast Cancer; 2020 Feb; 20(1):e20-e26. PubMed ID: 31631016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
    Bianco N; Milano M; Pagan E; Oriecuia C; Bagnardi V; Rocco EG; Santomauro GI; Peruzzotti G; Colleoni M; Viale G
    Breast Cancer Res Treat; 2022 Jan; 191(1):137-145. PubMed ID: 34609640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer.
    Ghebeh H; Elshenawy MA; AlSayed AD; Al-Tweigeri T
    Immunotherapy; 2022 Mar; 14(4):189-199. PubMed ID: 34984928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.
    Luhn P; Chui SY; Hsieh AF; Yi J; Mecke A; Bajaj PS; Hasnain W; Falgas A; Ton TG; Kurian AW
    J Comp Eff Res; 2019 Oct; 8(14):1173-1185. PubMed ID: 31394922
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.